Mutant ras oncogenes and alterations in the mitogenic signaling pathways that they regulate are associated with a wide variety of solid tumors and leukemias for which existing chemotherapeutics have limited utility. Of the possible approaches to inhibit Ras function, much attention has focused on a posttranslational modification, farnesylation, which is required for the subcellular localization of Ras to the plasma membrane and is critical to Ras cell-transforming activity. Inhibitors of the enzyme that catalyzes Ras farnesylation, farnesyl-protein transferase (FPTase), have been developed. These compounds inhibit the tumorigenic phenotypes of ras-transformed cells and human tumor cells in cell culture and in animal models. Moreover, FPTase inhibitors have not demonstrated toxicity to normal cells in culture or to normal tissues in mice. FPTase inhibitors are among the first small molecule compounds designed from studies of oncogenes that might serve as novel cancer chemotherapeutics.
INTRODUCTION
The need for new chemotherapeutics in cancer is evident from the limited capacity of existing agents to cure or significantly prolong the survival of patients with disseminated tumors or certain leukemias. The explosion of information on the biological complexities of cancer and the molecular genetic defects underlying tumorigenesis has afforded new opportunities for cancer drug discovery and development (1, 2) . The therapeutic goal is to capitalize on this new information and translate it into novel biological and pharmacological agents that will demonstrate greater efficacy and lower toxicity than currently available cancer cytotoxic drugs. Among some of the most commonly occurring mutations in cancer are alterations of the ras genes [Harvey (Ha), Kirsten (Ki), and N-ras] (3) (4) (5) . The ras genes encode 21-kDa proteins, called p21 or Ras, that are localized to the inner face of the plasma membrane. Ras binds GTP and GDP and serves as a molecular switch, interfacing between receptors and intracellular effector proteins. When Ras is stimulated by receptor activation to bind GTP, it promotes cell proliferation. The GTPase activity of Ras then turns off the biological event. The mutations in ras genes most often found in cancer inhibit Ras GTPase activity, so Ras remains bound to GTP and constitutively stimulates cell growth (i.e. the switch is stuck in the "on" position). Alterations in the function of ras gene products, particularly Ki4B-Ras and N-Ras, are found in many different tumors, including carcinomas of the colon, pancreas, and lung; neurofibrosarcomas; and various leukemias, including both adult and juvenile chronic myelogenous leukemia (3, (6) (7) (8) (9) .
Many approaches have been considered to inhibit the function of oncogenic Ras and subsequent cellular transformation induced by mutant ras (10) (11) (12) (13) . The greatest progress toward developing novel chemotherapeutics against rasinduced cell transformation has centered on inhibiting the enzyme farnesylprotein transferase (FPTase) (14) (15) (16) (17) (18) (19) . FPTase is an enzyme that catalyzes the addition of a farnesyl isoprene group to a number of cellular proteins as a form of posttranslational modification. One of the classes of proteins modified by FPTase is the Ras family, whose members include Ha-, Ki-, and N-Ras. The addition of the farnesyl group is required to convert Ras from a cytoplasmic and biologically inactive precursor protein into a fully mature membrane-associated protein (5) . Farnesylation occurs at the C terminus of Ras in a region called a CaaX box (C, Cys; a, usually aliphatic amino acid; X, another amino acid). This reaction is followed by several other posttranslational modifications (see below and Figure 1 ). However, it is the FPTase reaction that is most critical to Ras cell-transforming activity (20) (21) (22) . The immediate implication of these findings that initiated interest in this enzyme as a therapeutic target was that inhibition of FPTase with a pharmacological agent would prevent Ras from maturing into its biologically active form. Therefore, an FPTase antagonist might inhibit ras-induced cell transformation.
Early proofs-of-principle studies supporting the idea that the farnesylation reaction was a potential anti-Ras therapeutic target initially came from genetic analyses of both mammalian and yeast Ras proteins. If the farnesylation acceptor site was mutated so that farnesylation could not occur, then oncogenic Ras Figure 1 Posttranslational modifications of CaaX-containing proteins. FPTase farnesylates CaaX substrates having C-terminal residues Ser, Met, and Gln (S, M, and Q). GGPTase-I prefers CaaX substrates having a C-terminal Leu (L). FPP, farnesyl diphosphate; GGPP, geranylgeranyl diphosphate.
proteins were no longer able to transform cells (5) . In yeast, RAS proteins, like their mammalian counterparts, are dependent upon farnesylation for membrane localization and function (22) . Furthermore, yeast RAS proteins having mutations analogous to those found in oncogenic mammalian Ras display phenotypes in yeast that are distinct from wild-type RAS. When FPTase is genetically ablated in yeast, mutant RAS proteins can no longer induce these unique phenotypes, indicating that their function has been suppressed (22) (23) (24) . Importantly, under these conditions, the genetic ablation of FPTase does not cause the yeast cells to die. These observations provided evidence that inhibition of FPTase, even though it is important to the function of a number of proteins other than Ras, would not be toxic to normal cells.
It is not our intent here to comprehensively review all aspects of this field. Instead, we wish to highlight some of the key observations that have been made about the biological development of FPTase inhibitors as cancer chemotherapeutics and to point out some of the drug development issues that lie ahead. Separate reviews provide details on the biology of Ras (4, 5, (25) (26) (27) , protein prenylation (28) (29) (30) , prenylation enzymology (31, 32) , and the structural diversity of FPTase inhibitors (14-17, 19, 33) .
HISTORICAL BACKGROUND
The initial connection between Ras and farnesylation occured in 1989 as a result of the convergence of three areas of research. In the field of oncogene biology, it had been known since 1980 that Ras was localized to the plasma membrane of cells and that a posttranslational modification was responsible for this event (5) . In 1984, Willumsen, Lowy, and coworkers further defined that a critical determinant for Ras membrane localization and cell-transforming activity was a posttranslational modification involving the Cys residue of the CaaX box, because a Cys to Ser substitution eliminated Ras cell-transforming activity (34) . Further studies of the biochemical nature of Ras indicated that mature Ras was also palmitoylated (5) . Finally, Clarke and Stock also found that Ras proteins could be methylated (21) . The second set of relevant observations came from the study of lipid modifications of mammalian proteins during the mid-1980s. Glomset and collaborators described a new posttranslational modification of proteins (30) . They observed that metabolites derived from mevalonic acid could be covalently incorporated into proteins (Figure 1 ). These observations were extended by Maltese and collaborators, who characterized the nature of these modified proteins (29); of particular note was the fact that most of the mevalonate-labeled proteins had molecular sizes near 20-kDa, and most were associated with the membrane fraction of cells.
Lastly, a series of observations became available from investigators studying the chemical nature of the posttranslational modifications of specific proteins in fungi, yeast, and mammalian cells. Using NMR and mass spectrometry, investigators found that fungal and yeast mating factors were modified at the C-terminal amino acid (Cys) by a farnesyl moiety (a metabolite of mevalonic acid) linked to the Cys via a thio-ether linkage. Additionally, it was found that the Cys carboxylate was methylated (35) (36) (37) . From the previous cloning of yeast a-mating factor, it was known that the protein is initially translated as a precursor polypeptide that possesses a CaaX box. Gelb, Glomset, and coworkers identified these same type of C-terminal chemical modifications in another CaaX protein, mammalian nuclear lamin B (38) .
These observations suggested that Ras protein is also modified at its Cterminal CaaX sequence by a series of posttranslational events that include farnesylation, proteolytic cleavage of the aaX residues, and methyl esterification of the now C-terminal Cys residue. Most importantly, these modifications appeared to be important for Ras cell-transforming activity. In 1989, three groups of investigators provided biochemical, genetic, and pharmacological evidence that the Ras proteins were indeed farnesylated and that farnesylation was essential to Ras function (39) (40) (41) . This work provided the intellectual foundations and impetus for further study of Ras protein prenylation reactions and their potential suitability as anticancer targets in the context of ras-induced cell transformation.
FUNDAMENTALS OF PROTEIN PRENYLATION
Prenylated proteins share characteristic C-terminal sequences, including CaaX, XXCC, or XCXC. Three posttranslational processing steps have been described for proteins having a C-terminal CaaX sequence: addition of either a 15-carbon (farnesyl) or 20-carbon (geranylgeranyl) isoprenoid to the Cys residue, proteolytic cleavage of the aaX peptide, and methylation of the new C-terminal carboxylate ( Figure 1 ) (21, 22) . Some proteins may also have a fourth modification: palmitoylation of one or two Cys residues N-terminal to the farnesylated Cys. Proteins terminating with an XXCC or XCXC motif are modified by geranylgeranylation and do not require an endoproteolytic processing step. Although some mammalian cell proteins terminating in XCXC are carboxymethylated, carboxymethylation does not follow prenylation of proteins terminating with an XXCC motif (21, 31) . For all of the prenylated proteins, addition of the isoprenoid is the first step and is required for the subsequent steps (42) .
Many proteins have been identified as substrates or potential substrates for prenylation. A listing of some mammalian CaaX proteins that are farnesylated or geranylgeranylated is shown in Table 1 . In addition to the Ras proteins, many of these other substrates have been shown to be oncogenic or have roles in mitogenic signaling. For example, R-Ras2/TC21 transforms fibroblast cells in culture and may function by activating at least some of the Ras effector targets, such as Raf and Ral-GDS (43, 44) . Rho and Rac proteins are necessary for the ability of Ras to induce cytoskeletal alterations that are part of cellular transformation (45) . More recently, the phosphoprotein tyrosine phosphatases PRL1/PTP-CaaX-1 and -2 that demonstrate elevated expression in regenerating liver and are able to transform rodent fibroblast cells have been identified as farnesylated proteins (46, 47) . However, farnesylated proteins clearly have important roles to play in normal cells: The nuclear lamins essential for nuclear structural integrity (see 48) , proteins of the retinal visual signal transduction system (transducin γ subunit, cGMP phosphodiesterase α, and rhodopsin kinase) (see 18) , the human homologue of the yeast molecular chaperone YDJ1 (49, 50) , the skeletal muscle phosphorylase kinase (51) , as well as other proteins yet to be identified or whose precise function is unknown (for example Pxf, RhoE, and Rap2) (18, 52, 53) are all thought to be farnesylated. Three enzymes have been described that catalyze protein prenylation: farnesyl-protein transferase (FPTase), geranylgeranyl-protein transferase type I (GGPTase-I), and geranylgeranyl-protein transferase type-II (GGPTase-II, also called Rab GGPTase). These enzymes are found in the soluble fraction of many organisms, including yeast, Drosophila, and vertebrates (21, 22, 31, 32) . Each of these enzymes selectively uses farnesyl diphosphate (FPP) or geranylgeranyl diphosphate (GGPP) as the isoprenoid donor and selectively recognizes the protein substrate. FPTase and GGPTase-I are α/β heterodimeric enzymes that share a common α subunit; the β subunits are distinct but share approximately 30% amino acid similarity. FPTase farnesylates CaaX-containing proteins that end most commonly with Ser, Met, or Gln ( Figure 1 ). GGPTase-I geranylgeranylates CaaX-containing proteins that usually end with Leu ( Figure 1 ). In addition to conferring specificity for FPTase or GGPTase-I, the terminal residue of CaaX also influences affinity for the enzyme. For example, proteins ending with a Ser, such as Ha-Ras, bind more weakly to FPTase than proteins having a Met, such as Ki4B-Ras and lamin B (54, 55) . The differences in affinity imply that proteins in cells will have different sensitivities to an FPTase inhibitor. CaaX tetrapeptides comprise the minimum domain required for FPTase and GGPTase-I interaction with the protein substrate (54) (55) (56) (57) . This observation served as the basis for the development of CaaX peptidomimetic inhibitors of FPTase. However, additional sequences outside of CaaX can also influence the kinetics of prenylation (57, 58) .
GGPTase-II has different α and β subunits and complexes with a third component (REP, Rab escort protein) that presents the protein substrate to the α/β catalytic subunits (32) . GGPTase-II modifies XXCC and XCXC proteins. The interaction between GGPTase-II and its protein substrates is complex, requiring protein sequences in addition to the C-terminal amino acids for recognition (32) .
Although these enzymes are highly selective for their respective substrates, the substrate specificities are not absolute. For example, FPTase can farnesylate CaaL-containing proteins in vitro (57, 59, 60) . GGPTase-I can geranylgeranylate normally farnesylated proteins such as Ki4B-Ras (58). Moreover, GGPTase-I can also farnesylate or geranylgeranylate a single substrate, Rho B (60, 61) . These later findings suggest that in cells treated with an FPTase inhibitor, cross prenylation by GGPTase-I may occur. This possibility is particularly important because it implies that GGPTase-I might be able to rescue the function of some proteins that are prevented from being farnesylated by an FPTase inhibitor (18, 58, 60) .
STRUCTURAL DIVERSITY OF FPTase INHIBITORS
The substrates of FPTase, FPP and CaaX tetrapeptides, and detailed kinetic information on the mechanism of the FPTase reaction have served as the basis for rational design of FPTase inhibitors. In addition, several FPTase inhibitors have been discovered by random screening of natural products, chemical collections, and combinatorial libraries. A number of these compounds have also demonstrated activity in cells (Figure 2 ). Recent reviews have comprehensively described the structural diversity and biological properties of FPTase inhibitors (14-17, 19, 33) . The inhibitors can be subdivided into three broad categories: compounds competitive with FPP, compounds competitive with CaaX, and bisubstrate analogs that combine features of both the FPP and CaaX mimetics. Certain compounds of each type are known to be highly potent for FPTase inhibition (showing low nanomolar affinity) while displaying little inhibitory activity toward GGPTase-I at up to 1000-fold higher concentrations. Furthermore, these compounds are not substrates for FPTase and therefore are true enzyme inhibitors. In each of these classes, the compounds modeled after the physiological substrate needed modifications to eliminate metabolic liabilities such as the phosphodiester linkages of FPP and the peptide bonds of CaaX, which are susceptible to rapid degradation by plasma and cellular enzymes.
The first reported cell-active FPTase inhibitors were compounds that are competitive with the FPP substrate of FPTase. Manumycin was identified by random screening of natural products, and L-704,272 was rationally designed from FPP (62, 63) (Figure 2 ). Both these compounds are devoid of labile linkages. Manumycin also lacks the charged phosphate, which is presumed to be a liability for efficient cell membrane permeance. Although these compounds have shown biological activity, compounds competitive with respect to FPP need to overcome the high avidity of FPTase for its substrate FPP. FPTase binds FPP with low nanomolar affinity, while cellular FPP concentrations are near micromolar. Thus, FPTase would be prebound with FPP at the time when the CaaX substrate is presented for catalysis. This scenario is also supported by enzyme kinetic data. Although FPTase can bind either FPP or CaaX substrates independently of one another, the enzyme in vitro shows a preferred kinetic pathway, in which FPP binds before the CaaX substrate (64) (65) (66) (67) . Thus, inhibitors of FPTase that are competitive with FPP require a very tight K i . In addition, these compounds would have to be selective for FPTase over other FPP-utilizing enzymes (Figure 1) .
The first reported CaaX peptidomimetics, L-731,734, BZA-5B, and B581, were derived from synthetics using CaaX tetrapeptide sequences as a template (Figure 2 ) (68) (69) (70) . Since peptides are rapidly degraded by intracellular proteases, these compounds required modifications to eliminate the labile peptide bonds. In addition, the C-terminal carboxylate rendered the compounds less active in cells because the negative charge impaired membrane penetration. An ester prodrug strategy served as one approach to temporarily mask the carboxylate charge. Although ester prodrug forms of FPTase inhibitors are often 100-to 1000-fold less active than the free carboxylate form at inhibiting FPTase, once in the cell, this prodrug is removed by esterases to give the active enzyme inhibitor. Several peptidomimetic FPTase inhibitors have now been reported from several laboratories (Figure 2 ). Although many structural variations can be introduced to positions corresponding to a 1 a 2 of CaaX, most of the early compounds shared the Cys residue and a C-terminal amino acid having a carboxylate that required a prodrug strategy. Thiols are subject to oxidation and are metabolically reactive. The prodrugs are susceptible to plasma esterases, giving the challenge of developing a prodrug resistant to plasma esterases but still sensitive to the intracellular esterases necessary to release the biochemically active form of the compound in tumor cells.
FTI-265, L-745,631, and SCH 44342 ( Figure 2 ) serve as examples of cell active nonpeptides that eliminate the prodrug strategy (71) (72) (73) . SCH 44342 also represents the first reported cell-active nonthiol FPTase inhibitor that is competitive for the CaaX substrate (71) . This compound was identified by random screening of an extensive chemical collection of antihistamines. More recently, a nonthiol derivative of the BMS tetrahydroisoquinoline has been reported (74) . Other nonthiol CaaX mimetics have been described in the patent literature (17) . Further insights into the design of FPTase inhibitors may derive from structural studies of ligands bound to the enzyme (75, 76) .
Kinetic analysis of FPTase revealed a sequential mechanism, raising the idea that compounds that mimic the transition state would be both highly potent and specific inhibitors of the enzyme (19, 65, 77) . Indeed, bisubstrate analogs have been described and have shown utility in cell-based assays ( Figure 2 ) (19, 78) . However, the potency and specificity reported for these initial compounds is very similar to that observed with the smaller CaaX mimetics (17, 78) . Although further modifications of bisubstrate analogs may improve potency beyond that achievable with FPP or CaaX mimetics alone, this gain in potency may be offset by the larger size of these molecules, which may compromise their pharmacological properties in vivo.
EFFICACY OF FPTase INHIBITORS

Cell Biology
In cells, FPTase inhibitors block cellular protein farnesylation. Most often, this is determined by examining the processing of specific proteins, such as HaRas or nuclear lamins, or more globally by [ 3 H]mevalonate labeling of cellular proteins (16, 18, 48, 52, (68) (69) (70) (71) 78) . The concentrations of FPTase inhibitors necessary to achieve this action are often 1000 times greater than the IC 50 for inhibition of FPTase in vitro, suggesting that impeded cellular penetration or other limitations to cell activity are occurring. In general, the inhibitors that are competitive with respect to CaaX protein substrate are more efficacious in this assay than compounds that are competitive with respect to FPP (14, 17, 62, 63, 68, 69) . In addition to inhibiting Ha-Ras protein, FPTase inhibitors block farnesylation of a number of proteins, including lamin A, lamin B, Pxf, and perhaps as many as 15 as yet uncharacterized polypeptides (48, 52, 70) . Thus, it is incorrect to refer to FPTase inhibitors as Ras inhibitors. However, the biochemical specificity of FPTase inhibitors is unquestioned, since these agents do not block geranylgeranylation of proteins (63, 68-71, 73, 78-80) .
The processing of Ki4B-Ras does not appear to be sensitive to FPTase inhibitors such as FTI-277, BZA-5B, and L-739,749, perhaps because Ki4B-Ras may be geranylgeranylated in cells treated with an FPTase inhibitor (see section on Geranylgeranylation, below) (81, 82) . This observation is of importance because it suggests a mechanism by which Ki4B-ras, the most frequently mutated ras allele in human cancer, might be biologically unaffected by the actions of an FPTase inhibitor.
Biological activity of FPTase inhibitors against Ha-ras-transformed rodent fibroblast cells has been demonstrated in cell culture assays that monitor key phenotypes of cellular transformation: anchorage-independent growth (68, 71, 72, 78, (83) (84) (85) (86) , the rapidity of growth in monolayer (69, 71, 78, 79, 87) , morphological transformation (69, 71, 78, 79, 87) , and alterations in the cytoskeleton (78, 87) . The concentrations of compound necessary to elicit these effects are similar to those necessary to block intracellular farnesylation, suggesting that the observed efficacy is mechanism based. A cytostatic effect for the actions of FPTase inhibitors on Ha-ras-transformed cells in monolayer is suggested by the observation that upon removal of an FPTase inhibitor from the cell culture media, the cells revert back to a transformed phenotype (69, 87) . In addition to inhibiting the growth of transformed fibroblasts, FPTase inhibitors also block the anchorage-independent growth of human tumor-derived cells (83, 84, 86, (88) (89) (90) . Many of these cells are epithelial in origin and have multiple genetic alterations, such as mutant Ki4B-ras, mutant p53, and deregulated myc expression, that are not present in genetically engineered rodent fibroblasts but are very common in primary human tumors. Human tumor cells with and without mutant ras alleles are sensitive to B581 and L-744,832, although the doses of these agents necessary to achieve this effect varied over a two-order-of-magnitude range and varied depending on the particular cell line tested (83, 89) . Thus, the action of FPTase inhibitors may target a broader set of tumors than first anticipated. In addition, the results raise the possibility that farnesylated proteins in addition to Ras may be responsible for the biological action of FPTase inhibitors.
An early goal of these cell-based assays was not only to demonstrate efficacy against ras-transformed cells but also to distinguish the actions of FPTase inhibitors from more traditional cytotoxic agents. To do this, the activity of FPTase inhibitors against ras-transformed cells was compared with that in cells transformed by other oncogenes. If FPTase inhibitors were truly inhibiting the function of transforming Ras proteins, then cells transformed by an activated oncogene such as Raf, which does not require prenylation to achieve full biological activity, should be less sensitive to these inhibitors. The experimental basis for this prediction was founded on work carried out by Stacey and collaborators, who showed that cells transformed by Raf were insensitive to the actions of a neutralizing Ras antibody or dominant negative forms of Ras (91, 92) . In all biological assays reported, cells transformed by raf have been resistant to the actions of FPTase inhibitors at doses used to inhibit cells transformed by Ha-ras, suggesting that the action of FPTase inhibitors and their growth inhibitory profile is very different from the profiles observed with standard cytotoxic chemotherapeutic agents (68, 79, 86, 87) .
Another control experiment for the biological actions of FPTase inhibitors was the use of cells transformed by a form of Ha-ras in which the Ras-CaaX sequence was purposefully mutated (-CVLS changed to -CVLL) so that it could serve as a substrate for GGPTase-I. It was predicted that cells transformed by this form of Ras should be resistant to the action of an FPTase inhibitor because the transforming Ras protein would no longer require FPTase to be posttranslationally modified. Indeed, cells transformed by Ras-CVLL have been reported to resist the action of FPTase inhibitors B581, BMS 186511, and SCH 44342 in assays of morphological transformation and cell culture focus formation (71, 78, 79) .
As a result of these various biological controls, in particular the resistance of raf-transformed cells to FPTase inhibitors, one would predict that FPTase inhibitors should block signaling pathways emanating from Ras. One of the best characterized of these pathways is the mitogen-activated protein kinase (MAPK) cascade, which is activated following Ras/Raf interaction. FTI-277, B581, and BZA-5B have been shown to inhibit MAPK activation in cells transformed by Ha-ras but not in cells transformed by the geranylgeranylated form of Ha-ras (79-81, 93). In contrast, FTI-277 was not effective at inhibiting the MAP kinase pathway in Ki4B-ras transformed cells because it did not inhibit processing of Ki4B-Ras (80, 81) .
Nonfarnesylated oncogenic Ha-Ras can exhibit a dominant negative effect and can inhibit the function of membrane-bound Ras in some circumstances (94) (95) (96) . Thus, even though inhibition of FPTase would be expected to affect the function of several farnesylated proteins, the potential generation of a dominant negative Ras protein would selectively inhibit the Ras transforming pathway (11) . Since wild-type Ras does not display the dominant negative phenotype, the observed inhibition would be selective for the tumor cells. In Ha-rastransformed cells, maximal inhibition of MAPK activation by BZA-5B is observed under conditions of incomplete inhibition of Ha-Ras processing (93) . Furthermore, soluble complexes of nonfarnesylated oncogenic Ha-Ras and Raf can be isolated from cells (80, 97) . These data are the first experimental evidence supporting the idea that the action of an FPTase inhibitor may involve not only inhibition of Ras localization to the membrane but also the generation of a soluble dominant negative form of Ras. Such a dominant negative form of Ras would be expected to sequester Ras effector targets and thereby prevent them from interacting with the residual membrane-associated Ras.
The potential biological activity and utility of FPTase inhibitors may also be broader than first anticipated. One example is in the area of radiological treatment of cancer. Oncogenes such as Ha-ras may confer radioresistance that impedes this conventional method of tumor treatment. In cell culture, FTI-277 induced radiosensitivity and augmented the irradiation-induced apoptosis of transformed cells (98) . This observation suggests that FPTase inhibitors may have utility as radiosensitizers. An FPTase inhibitor has also been shown to block the expression of vascular endothelial-derived growth factor (VEGF) from Ha-ras-transformed cells. This observation suggests that the antitumor activity of FPTase inhibitors in animals may be due in part to the inhibition of tumor angiogenesis, which is critical for providing adequate blood supplies to the expanding tumor (99) .
Animal Biology
FPTase inhibitors have demonstrated antitumor efficacy in mice (62, 72, (83) (84) (85) (86) 100) . Initial studies utilized nude mice so that xenograft tumors could be produced using transformed rodent fibroblasts that were characterized for their sensitivity to FPTase inhibitors in cell culture. In this assay, the compounds are used to block tumor formation. As was observed in cell culture, tumors arising from Ha-ras-transformed cells were inhibited, whereas tumors arising from cells transformed by raf or mos showed resistance. The metabolic liability of the ester prodrug of FPTase inhibitors became evident in this assay. In some cases, the free carboxylate forms of the FPTase inhibitor were just as efficacious as the prodrug forms (FTI-276/FTI-277 and B956/B1086) (83, 84) . This result may vary among compounds because the acid of L-739,749 had poorer antitumor activity than the prodrug (86) . Nevertheless, given the high plasma esterase activity in rodents, this result is perhaps not so surprising and is probably a major reason why the doses required to achieve an antitumor effect (40-250 mg compound/kg of body weight) were so high. However, a clear dose-response relationship was observed between antitumor activity and the exposure to active drug (as measured by inhibition of Ha-Ras processing in the tumor) (83, 84) . Thus, in spite of the high doses required with these prototype compounds, the mechanism of antitumor activity seems to be related to inhibition of cellular FPTase.
Human tumor cells also show sensitivity to FPTase inhibitors in the nude mouse xenograft model (83, 84, 100) . However, not all human tumor cells were equally sensitive. Garcia and coworkers have suggested that the sensitivity of human tumor cells in this assay correlates with ras-mutational status (83) . They showed that cells that have mutant Ha-ras appear to be more sensitive than cells that have mutant N-or Ki4B-ras. The antitumor activity of FPTase inhibitors in nude mouse xenograft models can also confer prolonged survival, as shown with tumor-bearing mice treated with either manumycin or the BMS tetrahydroisoquinoline compound (62, 85) . So far, toxicity has not been reported in mice treated with any of the FPTase inhibitors tested. This observation is in sharp contrast to findings with cytotoxic agents, which often must be used at their maximally tolerated dose to obtain antitumor activity. Furthermore, a comparison of an FPTase inhibitor (L-739,749) with doxorubicin showed that the FPTase inhibitor was more efficacious in nude mice bearing Ha-ras-transformed tumors (86) .
One of the more unexpected actions of FPTase inhibitors in animals was seen in a transgenic mouse model of mammary cancer (101) . In this model, viral Ha-ras is expressed under the control of the MMTV promoter, and mice develop mammary and salivary carcinomas stochastically (102) . Thus, it appears that a second genetic alteration must occur in these animals before they develop tumors. In contrast to the nude mouse tumor models, the FPTase inhibitor is administered to these transgenic mice with preexisting tumors. Upon daily treatment of animals bearing small (50-150 mm 3 ) tumors with L-744,832, tumor regression was observed in 100% of the mice within a few days time, after which the tumor was not palpable and no new tumors appeared during up to 11 weeks of treatment (101) . Chronic administration of L-744,832 was required as tumors reappeared upon cessation of treatment. The results of FPTase inhibition in this model were also superior to the modest effects seen with doxorubicin. In mice having larger tumors (2000 mm 3 ), L-744,832 treatment also induced regression, although the response rate was 60%. The mechanisms underlying the observed tumor regression induced by L-744,832 or the tumor resistance were not reported (101) . At necropsy, histological examination showed evidence of some residual tumor in the L-744,832-treated mice, although the tumor's appearance was more differentiated than the observed tumor sections taken from vehicle-treated animals. Transgenic mice treated with L-744,832 for up to 11 weeks did not exhibit overt toxicity, as measured by total body weight. Moreover, the histological appearance of normal tissues that possess rapidly proliferating cells such as bone marrow and intestinal crypt cells or those tissues expressing tissue-specific farnesylated proteins such as retina and skeletal muscle were normal. As striking as these results are, it is prudent to remember that this model is based on overexpression of mutant Ha-Ras, which is particularly sensitive to FPTase inhibitors. Additionally the relevance of these observations to breast cancer is unclear, since human cancers of the breast rarely possess mutant ras genes. Furthermore, this transgenic model still does not approach the genetic complexity of human cancers, which often have multiple genetic alterations in oncogenes, tumor suppressors, and DNA repair pathways (103, 104) .
Nonmammalian Biology
The evaluation of FPTase inhibitors in nonmammalian systems has provided further support for the mechanism-based efficacy of these compounds. Manumycin was first identified in an S. cerevisiae cell-based assay (62) . This assay took advantage of the fact that growth inhibition induced by α-mating factor was dependent upon a signal transduction pathway having an essential protein that is farnesylated, Ste18, which is the γ subunit of the heterotrimeric G protein coupled to the mating factor receptor. Thus an FPTase inhibitor, selected from a random chemical sample, would be scored by observing cell growth in the presence of mating factor. The discovery of manumycin in this assay was a pharmacological demonstration (as would be predicted by the earlier genetic experiments) that an FPTase inhibitor could have biological efficacy in yeast and that the effects of such an inhibitor were not necessarily deleterious to yeast cell growth.
The efficacy of FPTase inhibitors has also been tested in other eucaryotic organisms such as Caenorhabditis elegans and Drosophila, in which ras genes have important physiological roles (105, 106) . In both these organisms, Ras controls cell fate and differentiation-vulva formation in C. elegans and R7 eye-cell formation in Drosophila-instead of growth proliferative properties found in mammalian cells. Activated Ras induces altered phenotypes in these organisms using signaling pathways that are conserved with those in mammalian cells (107, 108) . This observation not only permits FPTase inhibitors to be evaluated for efficacy, but by using organisms having activated Ras-signaling pathways at points downstream of the Ras protein, the biological specificity can also be addressed. In C. elegans, manumycin effectively inhibited the multivulva phenotype induced by activated ras but not that induced by the downstream mutant lin-1, indicating specificity for the action of manumycin (105) . The peptidomimetic BZA-5B was unable to elicit any effects in C. elegans, most likely because of impaired penetration into the organism. Kauffmann et al (106) reported that FPTase inhibitors injected into Drosophila eyes could block the phenotypes induced by activated Ras. Interestingly, the action of these compounds in Drosophila may be due to weak inhibitory activity towards GGPTase-I. The Drosophila Ras CaaX has a C-terminal Leu residue that should direct geranylgeranylation, and a genetic defect in GGPTase-I suppresses the phenotypes of activated Drosophila Ras (109) . Nevertheless, the action of the FPTase inhibitor appeared to be dependent upon inhibition of Ras prenylation. The compound was without effect in flies having activated Raf or an engineered form of Ras that functions independent of prenylation because of an N-terminal myristoylation posttranslational modification (106) . Although the physiology of Ras in C. elegans and Drosophila is quite different than that in mammalian cells, the observed results with FPTase inhibitors yielded the same conclusion: The actions of FPTase inhibitors block the activated Ras phenotype and do so apparently without affecting normal cells.
ISSUES ON THE BIOLOGICAL ACTIVITIES AND LIMITATIONS OF FPTase INHIBITORS
Selectivity for Tumor Cells
Although the biological results seen with FPTase inhibitors are widely accepted, one of the most common questions is, "Why is there selectivity for tumor cells versus normal cells?" The precise reasons for this phenomenon have not been established, but several observations that speak to this issue are notable. First, not all farnesylated proteins have the same sensitivity to FPTase inhibition in cells. Ha-Ras appears to be one of the more sensitive polypeptides to the action of FPTase inhibitors. Approximately ten-times-higher concentrations of FPTase inhibitors such as BZA-5B and B581 are required to achieve the same degree of farnesylation inhibition of the lamin proteins A and B (48, 69, 70) . Second, in the absence of functional FPTase, some proteins may serve as substrates for GGPTase-I (60). The functional impact of geranylgeranylation on these proteins cannot clearly be anticipated, but in the case of Ki4B-Ras, which serves as a good substrate for GGPTase-I, the oncogenic forms of Ki4B-Ras that are geranylgeranylated can effectively transform cells (58, 110) . Geranylgeranylated wild-type Ki4B-Ras may also provide critical biological functions to normal cells, although geranylgeranylated wild-type Ha-Ras has been reported to exhibit dominant negative properties (111) . Third, it is possible that redundant pathways in normal cells compensate for the functional loss of proteins such as Ha-Ras. For example, MAPK activation by growth factors such as EGF is not sensitive to BZA-5B (93) . This result most likely stems from the fact that the EGF receptor-signaling pathways are redundant with Ras or may involve proteins that are insensitive to the action of an FPTase inhibitor. Fourth, it remains unclear what degree of inhibition of farnesylation is required to block biological functions for any given protein, i.e. the quantitative relationship between a specific protein's function and its degree of farnesylation may vary. In this model, one would predict that the functions of farnesylated proteins involved with cellular transformation are more sensitive to the action of an FPTase inhibitor than are the functions of those same proteins in normal cells. Indeed, a dominant negative form of Ras has been found to exhibit a much greater inhibitory effect on cellular transformation induced by oncogenic Ha-Ras function than on normal cellular Ras function (95) .
Geranylgeranylation
In addition to the development of FPTase inhibitors, there has also been interest in the potential utility of GGPTase-I inhibitors. At the onset of programs directed at inhibiting FPTase, it was considered desirable to design compounds highly specific for FPTase in order to minimize the anticipated toxicities that might occur upon inhibition of both protein farnesylation and geranylgeranylation. Now, several geranylgeranylated proteins such as Rho, Rac, and R-Ras2/TC21 have been shown to play important roles in the control of cellular transformation. Rho and Rac proteins regulate the cytoskeletal arrangements and the morphological alterations induced by oncogenic Ras (45) . R-Ras2/TC21 is a highly potent oncogene protein; however, cellular transformation by R-Ras2/TC21 is resistant to the FPTase inhibitor BMS 186511 (44) . Thus, an inhibitor of the geranylgeranylation of these proteins might exhibit antitumor effects.
Several inhibitors of GGPTase-I have been reported. In each case, the compounds originated from FPTase inhibitors that were then altered by substituting a Leu residue at the terminal position (69, 81, 112) . The first reported cell active GGPTase-I inhibitor is GGTI-278, which is a Leu for Met substitution of . This compound is a highly potent GGPTase-I inhibitor and shows a fivefold selectivity for GGPTase-I over FPTase. GGTI-278 inhibits the processing of geranylgeranylated proteins such as Rap1 and Ki4B-Ras. The activity of GGTI-278 on Ki4B-Ras is surprising, since this protein is a better substrate for FPTase than for GGPTase-I, and two different studies have indicated that Ki4B-Ras is farnesylated in cells. Casey et al (39) immunoprecipitated Ki4B-Ras from cells radiolabelled with [ 3 H]mevalonic acid, a precursor of both farnesyl diphosphate and geranylgeranyl diphosphate (Figure 1) , and identified only a farnesyl moiety after methyl iodide cleavage. Because this method depends on conditions of mevalonate starvation in order to attain a high specific activity of [ 3 H]mevalonic acid, it may underrepresent geranylgeranylation (113) . Lowe and coworkers characterized the C-terminal modifications of Ki4B-Ras purified after heterologous expression in Sf9 insect cells by mass electrospray technique (114) . Although Sf9 cells will support geranylgeranylation of CaaX substrates (115) , only farnesyl was detected bound to Ki4B-Ras. Nevertheless, Sebti, Hamilton, and coworkers (81) and Brown, Goldstein, and coworkers (82) suggested that in cells treated with an FPTase inhibitor, Ki4B-Ras processing may not be inhibited by FPTase inhibitors because Ki4B-Ras can serve as a substrate for geranylgeranylation. The observations with GGTI-278 provide the first pharmacological evidence that cross-prenylation may be occurring in cells (81) , and a preliminary report using the [ 3 H]mevalonic acid labeling method has provided chemical evidence in support of this possibility (88) . Since a form of Ki4B-Ras that has its CaaX sequence mutated so as to be a substrate for GGPTase-I can induce cellular transformation (110) , the implication of this work is that Ki4B-ras-transformed cells would be resistant to the action of FPTase inhibitors.
Some reports have demonstrated that cells transformed by Ki4B-ras are less sensitive to an FPTase inhibitor than those transformed by Ha-ras, which is not a substrate for GGPTase-I (82, 83) . Others have reported efficacy against the anchorage-dependent and anchorage-independent growth of transformed rodent fibroblasts and human-tumor-derived epithelial cells expressing mutant Ki4B-Ras (78, 86, 89). As discussed above, the sensitivity of human tumor cells to L-744,832 does not appear to correlate with their ras mutational status (89) . Indeed, rodent fibroblast cells transformed by an N-terminally myristoylated form of Ha-Ras (which also has a Cys-to-Ser mutation it its CaaX box so that it can neither be farnesylated nor geranylgeranylated) are sensitive to L-739,749 in an anchorage-independent growth assay (116). These results have raised the possibility that other farnesylated proteins in addition to Ras proteins contribute to the biological phenotypes elicited by FPTase inhibitors in cells (12) .
Role of Other Farnesylated Proteins
The formal possibility that the biology of FPTase inhibition may involve proteins in addition to Ras was first raised from studies in yeast. Suppression of the activated RAS2 heat-shock phenotype by genetic disruption of FPTase may involve inhibition not only of RAS2 function but also of the molecular chaperone YDJ1, which is farnesylated (49) . YDJ1 may also influence proliferative functions in yeast such as the regulation of cyclins (117) . By this analogy, other farnesylated proteins in mammalian cells may be involved with the antitumorigenic action of FPTase inhibitors. One candidate is RhoB, which appears to function downstream of Ras, as evidenced by the observation that a dominant negative form of RhoB can block cellular transformation by Ras (118) . RhoB has been reported to be farnesylated and geranylgeranylated in cells and in vitro, although interestingly the catalyzing enzyme for both reactions appears to be GGPTase-I (61, 119) . In spite of the enzymology, RhoB subcellular localization is altered upon treating cells with L-739,749 (116) . Moreover, an activated and myristoylated form of RhoB (which is no longer a substrate for prenylation) confers about tenfold resistance to L-739,749 in Ha-ras-transformed cells (116) . Because the resistance conferred by this form of RhoB is only about tenfold and not absolute, other proteins could also be involved in the biological response of FPTase inhibitors. Recent candidates for such proteins include the two tyrosine phosphatases PRL1/PTP-CaaX, which based on a preliminary report, are capable of inducing tumorigenic properties in cells (46, 47) . Moreover, James et al (52) showed that the farnesylation of as many as 18 different polypeptides are sensitive to BZA-5B, leaving open the possibility that as yet uncharacterized farnesylated proteins may also have roles to play in the regulation of cellular proliferation.
SUMMARY AND FUTURE DIRECTIONS
The results obtained so far with FPTase inhibitors reinforce the notion that compounds designed from our understanding of the primary molecular defects in cancer will be more efficacious and less toxic than traditional cytotoxic agents. Similar successes have been seen with specific inhibitors of protein kinases (1) . Nevertheless, in spite of the striking results in preclinical models, it is still unproven that inhibitors developed in this manner will demonstrate efficacy in the clinic. FPTase inhibitors, like any experimental cancer drug, still have to overcome multiple hurdles. First, the prototype compounds must be modified so that they exhibit appropriate pharmacological features. Then, the compounds will be challenged by the genetic complexity of human cancer that involves alterations of oncogenes, tumor suppressors, and cell-cycle surveillance mechanisms (103, 104) . Although the experimental cell lines and tumor models may exhibit some of these features, they do not fully represent the genomic instability of real human tumors. In addition, the pathophysiology of these experimental tumors is not the same as human tumors with regard to the barriers an inhibitor must pass through to effectively penetrate all cells in the tumor mass (120) . Furthermore, the preclinical models suggest that FPTase inhibitors may require chronic administration to be fully efficacious. This method of treatment raises the issue of drug resistance and long-term toxicity as possible limitations to the use of these compounds. Resistance to FPTase inhibitors has been noted in both cell culture and in animal tumor models (82, 83, 89, 101, 121) . Although FPTase inhibitors so far have appeared safe in rodents, functional toxicity to specific organs (for example, the visual signal transduction system) may not be noted in rodents. Furthermore, rodents may not fully predict other potential toxicities in humans.
The field of protein prenylation and the biology of FPTase inhibitors as potential cancer chemotherapeutics is more complex than the simple hypotheses that provided the origins of this approach eight years ago. We can no longer think of these compounds as Ras-specific inhibitors. Although the biology observed with FPTase inhibitors is mechanism based, the precise target proteins involved with this response will continue to be an area of intense research. It is clear that there is much to be learned, and undoubtedly many surprises remain to be uncovered. For example, the tumor regression observed in Ha-ras transgenic mice treated with an FPTase inhibitor would not have been predicted based on our understanding of FPTase inhibitor action in cell culture or nude mice. Nevertheless, the gestalt provided by the accumulated biological observations obtained to date with multiple and structurally diverse FPTase inhibitors suggests that these agents possess remarkable potential as anticancer agents. The preclinical data accumulated thus far clearly merits further investigation and provides a sound rationale for moving these agents into clinical trials.
